The Life Sciences Innovative Manufacturing Fund (LSIMF)

The Life Sciences Innovative Manufacturing Fund (LSIMF) is a capital grants fund which aims to build resilience for future health emergencies and capitalise on the UK’s world-leading research and development capabilities. The fund will enhance and accelerate affordable access to mature, new and emerging Life Sciences products for both pandemic and non-pandemic scenarios. LSIMF will provide up to £520 million in capital grants for investment in the manufacture of human medicines and medical technology (including diagnostics, and MedTech products). This is a new fund from previous UK Government Life Sciences manufacturing funds. LSIMF is open to all eligible companies, including previous manufacturing grant recipients, as long as the application is for a different project. Projects with a total cost (including capital expenditure) of at least £8 million are eligible to apply. The maximum intervention rate (ratio of grant to project costs) is 25%, with the typical intervention rate being 10-20% of your total project costs. For example, for a project with a total cost of £100m, the typical grant awarded might be £10-20m. Contains public sector information from Find a grant, licensed under the Open Government Licence v3.0.

Your company To be eligible to apply for the fund, your company must be: A UK registered company, or a UK registered establishment UK establishments must also have at least one UK registered company in their group structure A wholly private sector business A product developer, contract development manufacturing organisation, or a generics manufacturer. Applicants must also be able to provide two years of audited accounts for the applicant company (and/or if applicable, parent entity). If this is not available – for example because the company is not required by Companies House to submit audited accounts – we will ask for demonstration that the remaining funding required for the project to go ahead is available. You may be also asked for evidence that your company (or if applicable, parent entity) has a track record of successfully manufacturing medicines or medical devices in the UK or abroad, or that you have successfully developed a product intended for commercial scale-up. Your proj...